Could a drug tame excess cortisol in a common hormone disorder?
NCT ID NCT07138274
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests whether the drug metyrapone can safely lower cortisol levels in people with mild autonomous cortisol secretion (MACS), a condition where the adrenal glands produce too much cortisol. Participants will receive either metyrapone or a placebo for a short period, and researchers will measure changes in hormone ratios and daily cortisol patterns. The goal is to see if metyrapone can help control the hormone imbalance and improve health outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
metyrapone
What this could lead to
If successful, metyrapone could offer a way to manage cortisol levels in people with MACS, potentially reducing related health risks.
What could go wrong
This is an early Phase 2 study with only 90 participants, so results may not apply broadly. Metyrapone can cause side effects like nausea or dizziness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD AUTONOMOUS CORTISOL SECRETION (MACS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••